Home › Peripheral Arterial Disease › Connecticut › New Haven
Peripheral Arterial Disease clinical trials in New Haven, CT
5 studies for Peripheral Arterial Disease are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
EVERO Drug-coated Balloon (DCB) Randomized Trial
Recruiting
- Yale New Haven Hospital, New Haven
CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions
RecruitingObservational study
- Yale New Haven Health, New Haven
SELUTION4BTK Trial
Recruiting
- Yale University, New Haven
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RecruitingPhase 3
- Yale School of Medicine, New Haven
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RecruitingPhase 4
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven · 3 mi away
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Cleveland, OH9 studies
- Boston, MA9 studies
- Chicago, IL9 studies
- Dallas, TX8 studies
- Houston, TX8 studies
- Gainesville, FL7 studies
- Omaha, NE7 studies
- Aurora, CO6 studies
- Nashville, TN6 studies
- Minneapolis, MN6 studies
- Miami, FL6 studies
- Atlanta, GA5 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)34 studies
- Lung Cancer23 studies
- Metastatic Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Prostate Cancer21 studies
- Colorectal Cancer21 studies
- Ovarian Cancer21 studies
- Acute Myeloid Leukemia19 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.